Seattle Life Sciences, ZymoGenetics deal

ZymoGenetics granted Seattle Life Sciences exclusive, worldwide rights to eight preclinical programs outside of ZymoGenetics' core focus of immunology. Seattle Life Sciences, a newco formed specifically to develop ZymoGenetics' preclinical portfolio, said potential indications for the programs include cancer, wound repair and kidney and liver fibrosis. ZymoGenetics is eligible to receive undisclosed milestones and royalties, plus an equity interest in Seattle Life contingent upon the newco obtaining venture capital financing. ...